Strategic Acquisition Following Lantheus’ $250M acquisition of Evergreen Theragnostics in 2025, there is a clear opportunity to align with the parent company’s expanded radiopharmaceutical portfolio, potentially enabling cross-sell of manufacturing, development, and regulatory services to Lantheus’ existing customer base.

CDMO Capability Evergreen’s strong focus as a radiopharmaceutical CDMO with expertise in process development and regulatory affairs presents a path to offer end-to-end manufacturing and development services for new theranostic radiopharmaceuticals, including GMP manufacturing and supply chain support.

Clinical Pipeline Active collaboration and licensing activities around EVG321 for small cell lung cancer and ongoing clinical development create opportunities to position specialized radioligand therapy development support, clinical trial manufacturing, and companion diagnostic commercialization services.

Expansion momentum Recent funding rounds and investments to expand discovery pipelines and CDMO capabilities indicate readiness for scaled manufacturing partnerships and accelerated commercialization efforts with pharmaceutical teams seeking rapid entry into radiopharmaceutical markets.

Strategic Partnerships Past collaborations with institutions like Medical University of Innsbruck and industry partners such as Jubilant Radiopharma signal a receptiveness to co-development and distribution agreements, suggesting outreach for alliance-led programs, licensing discussions, and joint go-to-market activities.